Senticell Secures $7M Seed Funding for Liquid Biopsy Technology

Senticell recently closed an oversubscribed seed financing round, raising nearly $7M to accelerate its medical testing platform. The Philadelphia based biotechnology startup builds a new type of liquid biopsy that relies on red blood cell nucleic acids. The Venture City, Capital Factory, Scalpel Ventures, and Evoce Capital supplied the capital alongside several private investors. The organization will direct this money toward ongoing clinical trials and further validation of its medical screening methods.

Rethinking Cancer Diagnostics

Most modern liquid biopsy tests examine blood plasma to locate signs of cancer. These conventional methods sometimes miss traces of the disease, especially during the earliest stages of tumor growth. Senticell takes a completely different path. The company analyzes the nucleic acids bound directly to red blood cells. By isolating these exact elements, the software and screening tools can detect oncogenic driver mutations that other tests might overlook entirely.

Chief Executive Officer Neha Shah leads the effort to bring this technology into regular medical settings. The platform, exclusively licensed from the University of Pennsylvania, targets low shedding tumors that release very little genetic material into the bloodstream. Finding these hidden signals gives doctors a much better chance to intervene early. Medical technology startups are receiving heavy financial backing to support patient health, similar to how Scan.com secured $220M in funding to expand its diagnostic network.

Ongoing Clinical Trials

The startup currently operates two major clinical studies at Penn Medicine involving roughly 300 patients. One trial monitors people diagnosed with lung and pancreatic cancer, focusing on detecting signals before surgery and tracking any signs of the disease returning. The second trial examines post treatment monitoring in patients with head and neck and cervical cancer.

The company expects to publish the results of the head and neck study by late 2026. Data from the lung and pancreatic group should arrive in early 2027. These trials will determine if the red blood cell method can accurately predict disease patterns better than the older plasma based standard.

Future Applications Beyond Oncology

While cancer detection remains the main priority, the engineering team sees other uses for their discovery. The scientific cofounder, Nilam Mangalmurti, noted that analyzing red blood cells gives doctors a distinct window into the human body. The team plans to test the platform for detecting pathogens linked to severe infections like sepsis and pneumonia. Moving away from slow laboratory cultures toward fast blood tests could save countless hours in emergency rooms.

The business also created a scientific advisory board filled with prominent doctors and scientists from Penn Medicine and Penn Vet, including Steven Albelda, Chris Hunter, and David Roth. This group will guide the company as it moves from laboratory research into commercial medical products. Investors continue to monitor early stage healthcare companies closely, matching the financial activity we covered when AIR secured $50M in seed funding for its own operations.

Read More on TechRobust:

• Google Rolls Out Pics Image Editor for AI Pro Subscribers
• Flutterwave hits three billion valuation with Ripple backing
• DeepSeek targets $74B valuation preparing for public listing